Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Bioreactor Controls-III01:22

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Bioplastics01:27

Bioplastics

Bioplastics derived from microbial processes present a sustainable alternative to conventional petroleum-based plastics. Among these, polyhydroxyalkanoates (PHAs), particularly polyhydroxybutyrates (PHBs), have emerged as prominent candidates due to their biodegradability and biocompatibility. These polymers are synthesized by a variety of bacteria, such as Cupriavidus necator and Pseudomonas putida, which naturally accumulate PHAs as intracellular carbon and energy reserves, especially under...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CHIMIA 2021, 75, 757.

Chimia·2023
Same author

A need for recalibrating access and benefit sharing: How best to improve conservation, sustainable use of biodiversity, and equitable benefit sharing in a mutually reinforcing manner?: How best to improve conservation, sustainable use of biodiversity, and equitable benefit sharing in a mutually reinforcing manner?

EMBO reports·2021
Same author

A Decade of Successful Collaborations in Nutritional Compound Process Research and Development.

Chimia·2021
Same author

From Sugars to Nutritional Products - Active Ingredients.

Chimia·2021
Same author

Adequate Vitamin D Intake Cannot Be Achieved within Carbon Emission Limits Unless Food Is Fortified: A Simulation Study.

Nutrients·2021
Same author

Time Dependence of Fluoride Uptake in Hydroxyapatite.

ACS biomaterials science & engineering·2021
Same journal

How Much Chirality is Enough?

Chimia·2026
Same journal

Raman Optical Activity (ROA) as an Emerging Standard in Molecular Chirality Measurements - A Perspective.

Chimia·2026
Same journal

Molecular Chirality: From Structure to the Quantum Dynamics of Tunnelling, Parity Violation, a Molecular Quantum Switch and the Possible Astrophysical Detection of Homochirality as a Signature of Extraterrestrial Life.

Chimia·2026
Same journal

Shining Light on Chiral Monolayer-protected Metal Clusters.

Chimia·2026
Same journal

Spin Depolarization Mechanisms in Halide Perovskite Semiconductors.

Chimia·2026
Same journal

New Insights into Circularly Polarized Luminescence from Chromium(III) Spin-Flip Emitters.

Chimia·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Way Forward for Biomanufacturing and Biotechnology in Europe.

Ulla Létinois1, Steven Crump2, Bastian Zerrer3

  • 1dsm-firmenich, Wurmisweg 576, CH-4303 Kaiseraugst, Switzerland. ulla.letinois@dsm-firmenich.com.

Chimia
|May 29, 2025
PubMed
Summary
This summary is machine-generated.

Achieving net zero emissions by 2050 requires a shift to a circular bioeconomy. This study examines the sustainability of biomanufactured vitamins and canthaxanthin in Europe, highlighting policy needs for industry competitiveness.

Keywords:
BioeconomyBiomanufacturingEcological footprintLife cycle assessmentSustainable sourcingVitamins

More Related Videos

The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

BioMEMS: Forging New Collaborations Between Biologists and Engineers
07:26

BioMEMS: Forging New Collaborations Between Biologists and Engineers

Published on: November 1, 2007

Related Experiment Videos

Last Updated: Jun 16, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

BioMEMS: Forging New Collaborations Between Biologists and Engineers
07:26

BioMEMS: Forging New Collaborations Between Biologists and Engineers

Published on: November 1, 2007

Area of Science:

  • Biotechnology and Sustainable Chemistry
  • Circular Economy and Climate Change Mitigation

Background:

  • Global warming necessitates reducing greenhouse gas emissions to net zero by 2050.
  • Transitioning to a circular, waste-free bioeconomy using renewable resources is crucial for sustainability.
  • The chemical sector transformation is vital for achieving climate goals.

Purpose of the Study:

  • To explore the sustainability benefits of key biomanufactured products: vitamins A and B2, and canthaxanthin.
  • To identify implementation opportunities and challenges for these products within Europe.
  • To inform policy for incentivizing the bioeconomy and ensuring industry competitiveness.

Main Methods:

  • Exploration of sustainability benefits.
  • Analysis of implementation opportunities and challenges in the European context.
  • Assessment of policy framework conditions for the biomanufacturing industry.

Main Results:

  • Biomanufactured vitamins A, B2, and canthaxanthin offer significant sustainability advantages.
  • Specific opportunities and challenges exist for their integration into the European market.
  • Policy frameworks are critical for enabling the bioeconomy's growth.

Conclusions:

  • Biomanufacturing is a key enabler for achieving net zero emissions.
  • Supportive European policies are essential to foster the bioeconomy and maintain industrial competitiveness.
  • Strategic transformation of the chemical sector is required for a sustainable future.